Literature DB >> 9751609

Constitutive and antibody-induced internalization of prostate-specific membrane antigen.

H Liu1, A K Rajasekaran, P Moy, Y Xia, S Kim, V Navarro, R Rahmati, N H Bander.   

Abstract

Prostate-specific membrane antigen (PSMA) is a cell surface glycoprotein expressed predominantly by prostate cancer cells. We have characterized four monoclonal antibodies that bind to the extracellular domain of PSMA (Liu et al., Cancer Res., 57: 3629-3634, 1997). Here we report that viable LNCaP cells internalize these antibodies. Laser scanning confocal microscopy reveals that the internalized antibodies accumulate in endosomes, and immunoelectron microscopy reveals that endocytosis of the PSMA-antibody complex occurs via clathrin-coated pits. In addition, a quantitative cell surface biotinylation assay demonstrates that PSMA is constitutively endocytosed in LNCaP cells and that anti-PSMA antibodies increase the rate of internalization of PSMA. These studies suggest that PSMA might function as a receptor mediating the internalization of a putative ligand. The availability of prostate-specific internalizing antibodies should aid the development of novel therapeutic methods to target the delivery of toxins, drugs, or short-range isotopes specifically to the interior of prostate cancer cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9751609

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  124 in total

Review 1.  Cell-specific aptamer-mediated targeted drug delivery.

Authors:  Jiehua Zhou; John J Rossi
Journal:  Oligonucleotides       Date:  2010-12-23

2.  Tomoregulin internalization confers selective cytotoxicity of immunotoxins on prostate cancer cells.

Authors:  Xiao-Yan Zhao; Hsiao-Lai Liu; Bing Liu; Joerg Willuda; Gerhard Siemeister; Mithra Mahmoudi; Harald Dinter
Journal:  Transl Oncol       Date:  2008-07       Impact factor: 4.243

3.  Spacer length effects on in vitro imaging and surface accessibility of fluorescent inhibitors of prostate specific membrane antigen.

Authors:  Tiancheng Liu; Jessie R Nedrow-Byers; Mark R Hopkins; Clifford E Berkman
Journal:  Bioorg Med Chem Lett       Date:  2011-10-04       Impact factor: 2.823

Review 4.  Current use of PSMA-PET in prostate cancer management.

Authors:  Tobias Maurer; Matthias Eiber; Markus Schwaiger; Jürgen E Gschwend
Journal:  Nat Rev Urol       Date:  2016-02-23       Impact factor: 14.432

5.  Comparison of Prostate-Specific Membrane Antigen Expression Levels in Human Salivary Glands to Non-Human Primates and Rodents.

Authors:  Jyoti Roy; Blake M Warner; Falguni Basuli; Xiang Zhang; Karen Wong; Thomas Pranzatelli; Anita T Ton; John A Chiorini; Peter L Choyke; Frank I Lin; Elaine M Jagoda
Journal:  Cancer Biother Radiopharm       Date:  2020-02-19       Impact factor: 3.099

6.  [¹⁷⁷Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer.

Authors:  Clemens Kratochwil; Frederik L Giesel; Matthias Eder; Ali Afshar-Oromieh; Martina Benešová; Walter Mier; Klaus Kopka; Uwe Haberkorn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-01-09       Impact factor: 9.236

7.  In vitro targeted photodynamic therapy with a pyropheophorbide--a conjugated inhibitor of prostate-specific membrane antigen.

Authors:  Tiancheng Liu; Lisa Y Wu; Joseph K Choi; Clifford E Berkman
Journal:  Prostate       Date:  2009-05-01       Impact factor: 4.104

Review 8.  New horizons in prostate cancer imaging.

Authors:  Gregory Ravizzini; Baris Turkbey; Karen Kurdziel; Peter L Choyke
Journal:  Eur J Radiol       Date:  2008-11-07       Impact factor: 3.528

Review 9.  Imaging in targeted delivery of therapy to cancer.

Authors:  Gairin Dancey; Richard H Begent; Tim Meyer
Journal:  Target Oncol       Date:  2009-10-08       Impact factor: 4.493

10.  Aptamer-targeted cell-specific RNA interference.

Authors:  Jiehua Zhou; John J Rossi
Journal:  Silence       Date:  2010-02-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.